Eiji Nakata

Dr. Eiji Nakata


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2021 in Healthcare
Verified
Journal Article
Open access
PDF file
MIMasato Ise
Masato Ise
ENEiji Nakata
Eiji Nakata
YKYoshimi Katayama
Yoshimi Katayama
MHMasanori Hamada
Masanori Hamada
TKToshiyuki Kunisada
Toshiyuki Kunisada
TOToshifumi Ozaki
Toshifumi Ozaki
Psychological distress is common in patients with soft tissue and bone tumors. We first investigated its frequency and the associated risk factors in patients with pre-operative bone and soft tissue tumors. Participants included 298 patients with bone and soft tissue tumors who underwent surgery in our institution between 2015 and 2020. Psychological distress was evaluated by the Distress and Impact Thermometer (DIT) that consists of two types of questions (questions about the severity of the patient’s distress (DIT-D) and its impact (DIT-I)). We used a cut-off point of 4 on the DIT-D and 3 on the DIT-I for screening patients with psychological distress. We therefore investigated: (1) the prevalence of psychological distress as assessed with DIT or distress thermometer (DT), which can be decided by DIT-D ≥ 4, (2) what are the risk factors for the prevalence of psychological distress, and (3) what is the number of patients who consulted a psychiatrist for psychological distress in patients with pre-operative bone and soft tissue tumors. With DIT and DT, we identified 64 patients (21%) and 95 patients (32%), respectively, with psychological distress. Multivariate logistic regression revealed that older age, sex (female), malignancy (malignant or intermediate tumor), a lower Barthel Index, and higher numeric rating scale were risk factors for psychological distress. Two patients (3%) consulted a psychiatrist after surgery. In conclusion, careful attention to psychological distress is needed, especially for female patients, older patients, and those with malignant soft or bone tissue tumors who have more than moderate pain.

26 January 2024 in Cancer Science
Verified
Journal Article
Open access
HKHaruyoshi Katayama
Haruyoshi Katayama
AFAtsushi Fujimura
Atsushi Fujimura
RHRongsheng Huang
Rongsheng Huang
YOYusuke Otani
Yusuke Otani
TITakuto Itano
Takuto Itano
TOToshifumi Ozaki
Toshifumi Ozaki
Malignant peripheral nerve sheath tumors (MPNSTs) are malignant tumors that are derived from Schwann cell lineage around peripheral nerves. As in many other cancer types, cancer stem cells (CSCs) have been identified in MPNSTs, and they are considered the cause of treatment resistance, recurrence, and metastasis. As an element defining the cancer stemness of MPNSTs, we previously reported a molecular mechanism by which exogenous adrenaline activates a core cancer stemness factor, YAP/TAZ, through β2 adrenoceptor (ADRB2). In this study, we found that MPNST cells express catecholamine synthases and that these enzymes are essential for maintaining cancer stemness, such as the ability to self‐renew and maintain an undifferentiated state. Through gene knockdown and inhibition of these enzymes, we confirmed that catecholamines are indeed synthesized in MPNST cells. The results confirmed that catecholamine synthase knockdown in MPNST cells reduces the activity of YAP/TAZ. These data suggest that a mechanism of YAP/TAZ activation by de novo synthesized adrenaline, as well as exogenous adrenaline, may exist in the maintenance of cancer stemness of MPNST cells. This mechanism not only helps to understand the pathology of MPNST, but could also contribute to the development of therapeutic strategies for MPNST.

17 March 2022 in Research Square
Verified
Preprint
Open access
PDF file
ENEiji Nakata
Eiji Nakata
TFTomohiro Fujiwara
Tomohiro Fujiwara
TKToshiyuki Kunisada
Toshiyuki Kunisada
HKHaruyoshi Katayama
Haruyoshi Katayama
HKHaruna Kondo
Haruna Kondo
TOToshifumi Ozaki
Toshifumi Ozaki
We aimed to investigate the efficacy and safety of denosumab de-escalation for giant cell tumors of the bone (GCTB). We retrospectively reviewed the medical records of nine patients with GCTB that were either unresectable or resectable, but not those of candidates for resection, who received de-escalated denosumab treatment at our institution between 2014 and 2021. The denosumab treatment interval was gradually extended to every 8 weeks, 12 weeks, and 24 weeks. We assessed the radiographic changes and clinical symptoms during the course of standard and de-escalated denosumab therapy. Denosumab interval was de-escalated after a median of 12 months of a standard 4-weekly treatment. Imaging showed that a good therapeutic response obtained with the 4-weekly treatment was sustained until the 8-weekly and 12-weekly treatment. According to the MD Anderson criteria, GCTB treated with de-escalated denosumab therapy resulted in a complete response in one patient and a partial response in eight patients, which were obtained with standard treatment. During the 24-weekly treatment, two patients remained stable, while one patient developed local recurrence. The extraskeletal mass reduced significantly with standard treatment, while tumor reduction was sustained during de-escalated treatment. The clinical symptoms significantly improved with standard treatment and remained improved during de-escalated treatment. In conclusion, de-escalated treatment of denosumab has clinical benefit as a maintenance treatment in patients with unresectable GCTB.